CA2501220C - Vaccines against west nile virus - Google Patents

Vaccines against west nile virus Download PDF

Info

Publication number: CA2501220C
Authority: CA; Canada
Prior art keywords: west nile; nile virus; per; virus; cells
Prior art date: 2002-11-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA2501220A

Other languages

English (en)

French (fr)

Other versions

CA2501220A1 (en

Inventor

Alphonsus Gerardus Cornelis Maria Uytdehaag

Govert Johan Schouten

Jaap Goudsmit

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Vaccines and Prevention BV

Original Assignee

Crucell Holand BV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-08

Filing date

2003-11-07

Publication date

2012-01-17

2003-11-07 Application filed by Crucell Holand BV filed Critical Crucell Holand BV

2004-05-21 Publication of CA2501220A1 publication Critical patent/CA2501220A1/en

2012-01-17 Application granted granted Critical

2012-01-17 Publication of CA2501220C publication Critical patent/CA2501220C/en

2023-11-07 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

241000710886 West Nile virus Species 0.000 title claims abstract description 211
229960005486 vaccine Drugs 0.000 title abstract description 134
241000700605 Viruses Species 0.000 claims description 71
238000000034 method Methods 0.000 claims description 66
208000015181 infectious disease Diseases 0.000 claims description 49
108020004707 nucleic acids Proteins 0.000 claims description 30
102000039446 nucleic acids Human genes 0.000 claims description 30
150000007523 nucleic acids Chemical class 0.000 claims description 30
238000004519 manufacturing process Methods 0.000 claims description 26
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 22
241000272814 Anser sp. Species 0.000 claims description 18
230000002779 inactivation Effects 0.000 claims description 13
238000012258 culturing Methods 0.000 claims description 7
230000000890 antigenic effect Effects 0.000 claims description 6
230000000415 inactivating effect Effects 0.000 claims description 6
238000003306 harvesting Methods 0.000 claims description 5
210000004027 cell Anatomy 0.000 abstract description 183
241000701161 unidentified adenovirus Species 0.000 abstract description 26
108010067390 Viral Proteins Proteins 0.000 abstract description 22
108090000623 proteins and genes Proteins 0.000 abstract description 20
210000005260 human cell Anatomy 0.000 abstract description 18
239000000725 suspension Substances 0.000 abstract description 10
239000002671 adjuvant Substances 0.000 description 53
241001465754 Metazoa Species 0.000 description 50
241000699666 Mus <mouse, genus> Species 0.000 description 48
239000002480 mineral oil Substances 0.000 description 38
235000010446 mineral oil Nutrition 0.000 description 38
210000004556 brain Anatomy 0.000 description 33
241000272808 Anser Species 0.000 description 30
241000282414 Homo sapiens Species 0.000 description 30
201000010099 disease Diseases 0.000 description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
238000002255 vaccination Methods 0.000 description 20
239000002609 medium Substances 0.000 description 19
241000710831 Flavivirus Species 0.000 description 18
230000004083 survival effect Effects 0.000 description 14
238000010790 dilution Methods 0.000 description 13
239000012895 dilution Substances 0.000 description 13
238000002360 preparation method Methods 0.000 description 13
210000003501 vero cell Anatomy 0.000 description 13
239000000047 product Substances 0.000 description 12
241000282412 Homo Species 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
241000699670 Mus sp. Species 0.000 description 10
230000000120 cytopathologic effect Effects 0.000 description 10
238000002347 injection Methods 0.000 description 10
239000007924 injection Substances 0.000 description 10
239000013642 negative control Substances 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 9
102100034349 Integrase Human genes 0.000 description 9
238000010240 RT-PCR analysis Methods 0.000 description 9
239000012091 fetal bovine serum Substances 0.000 description 9
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 8
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 8
239000006228 supernatant Substances 0.000 description 8
238000003556 assay Methods 0.000 description 7
238000007912 intraperitoneal administration Methods 0.000 description 7
239000000463 material Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
238000004113 cell culture Methods 0.000 description 6
239000012228 culture supernatant Substances 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
239000000203 mixture Substances 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
241000282693 Cercopithecidae Species 0.000 description 5
101710091045 Envelope protein Proteins 0.000 description 5
231100000111 LD50 Toxicity 0.000 description 5
101710188315 Protein X Proteins 0.000 description 5
206010057293 West Nile viral infection Diseases 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000000694 effects Effects 0.000 description 5
230000014509 gene expression Effects 0.000 description 5
238000007429 general method Methods 0.000 description 5
238000007917 intracranial administration Methods 0.000 description 5
239000000523 sample Substances 0.000 description 5
238000013207 serial dilution Methods 0.000 description 5
238000004448 titration Methods 0.000 description 5
108020004414 DNA Proteins 0.000 description 4
241000255925 Diptera Species 0.000 description 4
101150075174 E1B gene Proteins 0.000 description 4
101710199711 Early E1A protein Proteins 0.000 description 4
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
241000710772 Yellow fever virus Species 0.000 description 4
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
229910052782 aluminium Inorganic materials 0.000 description 4
229910021502 aluminium hydroxide Inorganic materials 0.000 description 4
229940001007 aluminium phosphate Drugs 0.000 description 4
229910000147 aluminium phosphate Inorganic materials 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
238000010586 diagram Methods 0.000 description 4
238000011031 large-scale manufacturing process Methods 0.000 description 4
239000013641 positive control Substances 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000011282 treatment Methods 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
229940051021 yellow-fever virus Drugs 0.000 description 4
241000114297 Bubo scandiacus Species 0.000 description 3
241000283086 Equidae Species 0.000 description 3
241000283073 Equus caballus Species 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
108020000999 Viral RNA Proteins 0.000 description 3
201000006449 West Nile encephalitis Diseases 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
238000011160 research Methods 0.000 description 3
239000013598 vector Substances 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
CXENHBSYCFFKJS-OXYODPPFSA-N (Z,E)-alpha-farnesene Chemical compound CC(C)=CCC\C(C)=C\C\C=C(\C)C=C CXENHBSYCFFKJS-OXYODPPFSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
241000271566 Aves Species 0.000 description 2
241001137251 Corvidae Species 0.000 description 2
241000350709 Culex annulirostris Species 0.000 description 2
241000710781 Flaviviridae Species 0.000 description 2
206010054261 Flavivirus infection Diseases 0.000 description 2
241000598171 Human adenovirus sp. Species 0.000 description 2
208000003152 Yellow Fever Diseases 0.000 description 2
230000002411 adverse Effects 0.000 description 2
229940037003 alum Drugs 0.000 description 2
210000001776 amniocyte Anatomy 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
239000012620 biological material Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
206010014599 encephalitis Diseases 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
244000144992 flock Species 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
229940031551 inactivated vaccine Drugs 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
244000005700 microbiome Species 0.000 description 2
238000003359 percent control normalization Methods 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
229960000380 propiolactone Drugs 0.000 description 2
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000012340 reverse transcriptase PCR Methods 0.000 description 2
239000012679 serum free medium Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
229940031626 subunit vaccine Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
241000036557 Accipiter cooperii Species 0.000 description 1
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
241000710929 Alphavirus Species 0.000 description 1
241000272809 Anser anser Species 0.000 description 1
241000238421 Arthropoda Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
241000256113 Culicidae Species 0.000 description 1
108010041986 DNA Vaccines Proteins 0.000 description 1
229940021995 DNA vaccine Drugs 0.000 description 1
206010012310 Dengue fever Diseases 0.000 description 1
241000725619 Dengue virus Species 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
241000711557 Hepacivirus Species 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102100040018 Interferon alpha-2 Human genes 0.000 description 1
102100026720 Interferon beta Human genes 0.000 description 1
108010079944 Interferon-alpha2b Proteins 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
241000710842 Japanese encephalitis virus Species 0.000 description 1
VSMWRDYVLPCABE-UHFFFAOYSA-N Justicidin E Natural products C1=C2OCOC2=CC(C2=C3C=C4OCOC4=CC3=CC3=C2COC3=O)=C1 VSMWRDYVLPCABE-UHFFFAOYSA-N 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000710908 Murray Valley encephalitis virus Species 0.000 description 1
241001197446 Mus cypriacus Species 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
241000710778 Pestivirus Species 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
241000710888 St. Louis encephalitis virus Species 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
208000010513 Stupor Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000710771 Tick-borne encephalitis virus Species 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
108010067674 Viral Nonstructural Proteins Proteins 0.000 description 1
241000120645 Yellow fever virus group Species 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
230000003321 amplification Effects 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
239000013590 bulk material Substances 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
150000001768 cations Chemical group 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
208000004209 confusion Diseases 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
208000025729 dengue disease Diseases 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
239000013024 dilution buffer Substances 0.000 description 1
206010013395 disorientation Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000011143 downstream manufacturing Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000012757 fluorescence staining Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000012252 genetic analysis Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000036541 health Effects 0.000 description 1
JUBRYHUFFFYTGR-UHFFFAOYSA-N helioxanthin Chemical compound C1=C2OCOC2=CC(C2=C3C=4OCOC=4C=CC3=CC3=C2COC3=O)=C1 JUBRYHUFFFYTGR-UHFFFAOYSA-N 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
244000052637 human pathogen Species 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000002276 neurotropic effect Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
231100001221 nontumorigenic Toxicity 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000008520 organization Effects 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
238000013081 phylogenetic analysis Methods 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000005180 public health Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
206010037844 rash Diseases 0.000 description 1
238000011897 real-time detection Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
239000003161 ribonuclease inhibitor Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000001626 skin fibroblast Anatomy 0.000 description 1
231100000046 skin rash Toxicity 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
230000001018 virulence Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Microbiology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA2501220A 2002-11-08 2003-11-07 Vaccines against west nile virus Expired - Fee Related CA2501220C (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
NLPCT/NL02/00718		2002-11-08
NLPCT/NL02/00718		2002-11-08
EPPCT/EP03/50129		2003-04-28
EPPCT/EP03/50129		2003-04-28
PCT/EP2003/050806 WO2004042042A1 (en)	2002-11-08	2003-11-07	Vaccines against west nile virus

Publications (2)

Publication Number	Publication Date
CA2501220A1 CA2501220A1 (en)	2004-05-21
CA2501220C true CA2501220C (en)	2012-01-17

Family

ID=32313778

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2501220A Expired - Fee Related CA2501220C (en)	2002-11-08	2003-11-07	Vaccines against west nile virus

Country Status (7)

Country	Link
AT (1)	ATE453708T1 (de)
AU (1)	AU2003298277B2 (de)
CA (1)	CA2501220C (de)
DE (1)	DE60330795D1 (de)
IL (1)	IL168374A (de)
NZ (1)	NZ538808A (de)
WO (1)	WO2004042042A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7927840B2 (en)	2006-09-11	2011-04-19	Gen Probe Incorporated	Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
US7115374B2 (en)	2002-10-16	2006-10-03	Gen-Probe Incorporated	Compositions and methods for detecting West Nile virus
US8052974B2 (en)	2005-05-12	2011-11-08	Crucell Holland B.V.	Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1724338A1 (de) *	2005-05-19	2006-11-22	Crucell Holland B.V.	Methode zur Herstellung eines Impfstoffs aus inaktiviertem ganzem Westnilvirus
WO2006122964A1 (en) *	2005-05-19	2006-11-23	Crucell Holland B.V.	Methods for the production of a whole-inactivated west nile virus vaccine
CA2612047C (en) *	2005-06-24	2015-05-12	Intervet International B.V.	Inactivated chimeric vaccines and related methods of use
KR101274790B1 (ko)	2005-07-22	2013-06-13	크루셀 홀란드 비.브이.	코로나바이러스 생산용 세포주

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1103610A1 (de) *	1999-11-26	2001-05-30	Introgene B.V.	Impfstoffherstellung von immortalisierten Säugetierzellinien
US20030148261A1 (en) *	2001-03-12	2003-08-07	Erol Fikrig	Compositions and methods comprising West Nile virus polypeptides

2003
- 2003-11-07 NZ NZ538808A patent/NZ538808A/en not_active IP Right Cessation
- 2003-11-07 CA CA2501220A patent/CA2501220C/en not_active Expired - Fee Related
- 2003-11-07 AT AT03796004T patent/ATE453708T1/de active
- 2003-11-07 DE DE60330795T patent/DE60330795D1/de not_active Expired - Lifetime
- 2003-11-07 AU AU2003298277A patent/AU2003298277B2/en not_active Ceased
- 2003-11-07 WO PCT/EP2003/050806 patent/WO2004042042A1/en not_active Ceased
2005
- 2005-05-03 IL IL168374A patent/IL168374A/en unknown

Also Published As

Publication number	Publication date
AU2003298277A1 (en)	2004-06-07
NZ538808A (en)	2008-03-28
WO2004042042A1 (en)	2004-05-21
CA2501220A1 (en)	2004-05-21
AU2003298277B2 (en)	2009-01-22
DE60330795D1 (de)	2010-02-11
IL168374A (en)	2010-11-30
ATE453708T1 (de)	2010-01-15

Legal Events

Date	Code	Title	Description
2008-10-30	EEER	Examination request
2013-12-19	MKLA	Lapsed	Effective date: 20131107

Publication	Publication Date	Title
US11753627B2 (en)	2023-09-12	Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
Powers	2018	Vaccine and therapeutic options to control chikungunya virus
Monath et al.	1999	Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates
Ikegami et al.	2009	Rift valley fever vaccines
US20090017068A1 (en)	2009-01-15	Vaccines against West Nile Virus
US7718359B2 (en)	2010-05-18	Method of immunization against the 4 serotypes of dengue fever
Srivastava et al.	2001	A purified inactivated Japanese encephalitis virus vaccine made in Vero cells
US20130095136A1 (en)	2013-04-18	Tetravalent Dengue Vaccines
Tretyakova et al.	2013	Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine
CN108289945B (zh)	2022-05-31	用于制备减毒四价登革热疫苗的方法
KR20180137514A (ko)	2018-12-27	어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법
WO2007094854A9 (en)	2007-11-01	Rna virus vaccines and methods
CA2501220C (en)	2012-01-17	Vaccines against west nile virus
Yamshchikov et al.	2016	Development of a human live attenuated West Nile infectious DNA vaccine: Suitability of attenuating mutations found in SA14-14-2 for WN vaccine design
US20070036827A1 (en)	2007-02-15	West nile virus vaccine
EP1558726B1 (de)	2009-12-30	Impfstoff gegen west nile virus
AU2019249329B2 (en)	2025-07-17	Live-attenuated yellow fever virus strain adapted to grow on Vero cells and vaccine composition comprising the same
Kuznetsova et al.	2022	Development and Characterization of Yellow Fever Virus Vaccine Strain 17DD-Based Chimeric Tick-Borne Encephalitis Virus
Williamson	1998	Poxvirus DNA-dependent RNA polymerase
CN116536277A (zh)	2023-08-04	虫媒黄病毒减毒株及其构建方法与应用
Rodríguez et al.	2016	Vaccine composition
Shueb	2008	Contribution of different components of innate and adaptive immunity to severity of flavivirus-induced encephalitis in susceptible and resistant hosts
HK1128729A (en)	2009-11-06	Recombinant polyvalent vaccine